LM
LeMaitre Vascular, Inc.
LMAT · NASDAQ
$80.38 +1.15% (+$0.91)
1M -1.40%
Market Cap $1.84B
P/E Ratio 27.97x
Div. Yield 1.18%
ROE 16.42%
Bulios Fair Price
$58.1
27.7% downside
Current Price
$80.38
Undervalued Fair Value Overvalued
According to Bulios Fair Price, LMAT is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
41 /100
Fair P/E 27.97x
EV/EBITDA 20.55x
PEG 1.02x
Growth
96 /100
Growing EPS growth 39.41%
Rev. growth 15.58%
Book val. growth 13.63%
Profitability
100 /100
Strong Gross margin 72.90%
Net margin 25.02%
FCF margin 28.13%
Quality
63 /100
Average ROIC 9.76%
ROE 16.42%
Asset turnover 0.41x
Debt
86 /100
Low Debt/Equity 0.45x
Current ratio 16.31x
Net debt/EBITDA 1.68x
Stability
93 /100
Stable Beta 0.49x
Rev. volatility 3.53%
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about LMAT
Online
Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
George W. LeMaitre
Employees
651
Headquarters
Burlington
Upcoming events
05 NOV
Earnings
Upcoming earnings report